Tisch Cancer Institute
- World rank, all time
- #18,486 of 42,892
- Rank in ??
- #268 of 1,041
- Research works
- 156 ▲ 91% vs 2013–17
- Citations
- 5.8k 37.0 per fractional work
- Top-10% rate
- 20.8% record average 16.5%
- Open access
- 50% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 5.4×. Every wedge is a field page.
- Immunology and Microbiology 5.4×
- Biochemistry, Genetics and Molecular Biology 3.6×
- Medicine 3.5×
- Neuroscience 0.9×
- Nursing 0.8×
- Health Professions 0.7×
- Economics, Econometrics and Finance 0.4×
- Chemistry 0.2×
- Psychology 0.2×
- Materials Science 0.1×
- Mathematics 0.1×
- Physics and Astronomy 0.1×
- Decision Sciences 0.1×
- Agricultural and Biological Sciences 0.1×
- Environmental Science 0.0×
- Computer Science 0.0×
- Engineering 0.0×
- Social Sciences 0.0×
Which keywords describe research at Tisch Cancer Institute?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Targeted Therapy, Cancer, Clinical Trials, Radiotherapy, Tumor Microenvironment and Cancer Immunotherapy.
- Survival Analysis
- Mutational Signatures
- Molecular Characterization
- Antigen Presentation
- Cancer Therapy
- Immune Checkpoint Blockade
- EGFR Mutations
- ALK Inhibitors
- Immunity
- Chimeric Antigen Receptor
- Leukemia
- Diagnosis Criteria
- Staging System
- Proteasome Inhibitors
- Lymphoma
- Prognostic Factors
- Cancer Immunotherapy
- Radiotherapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Cancer
- Clinical Trials
- Tumor Microenvironment
- Breast Cancer
- Gene Expression
- Neoadjuvant Therapy
- Minimal Residual Disease
- Tumor Regression
- International Myeloma Working Group
- CAR T Cells
- Genomic Profiling
- Clinical Practice Guidelines
- Biomarkers
- Genomic Instability
- PD-1 and PD-L1
- Metastatic Breast Cancer
- Cancer Genomics
- Molecular Subtypes
- Survival
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy5▲ 17×15 topics
- Immunotherapy5▲ 16×13 topics
- Cancer4▲ 6.4×22 topics
- Targeted Therapy4▲ 38×5 topics
- Clinical Trials3▲ 11×7 topics
- Radiotherapy3▲ 19×8 topics
- Tumor Microenvironment3▲ 15×6 topics
- Cancer Immunotherapy3▲ 43×2 topics
- Breast Cancer3▲ 26×8 topics
- Prognostic Factors3▲ 15×8 topics
- Gene Expression3▲ 9.6×8 topics
- Lymphoma3▲ 37×3 topics
- Neoadjuvant Therapy2▲ 24×4 topics
- Proteasome Inhibitors2▲ 74×2 topics
- Minimal Residual Disease2▲ 73×2 topics
- Staging System2▲ 76×2 topics
- Tumor Regression2▲ 42×2 topics
- Diagnosis Criteria2▲ 130×1 topic
- International Myeloma Working Group2▲ 130×1 topic
- Leukemia2▲ 53×2 topics
- CAR T Cells2▲ 56×1 topic
- Chimeric Antigen Receptor2▲ 56×1 topic
- Genomic Profiling2▲ 40×2 topics
- Immunity2▲ 10×5 topics
- Clinical Practice Guidelines2▲ 7.1×5 topics
- ALK Inhibitors2▲ 58×1 topic
- Biomarkers2▲ 5.3×6 topics
- EGFR Mutations2▲ 58×1 topic
- Genomic Instability2▲ 32×2 topics
- Immune Checkpoint Blockade2▲ 33×1 topic
- PD-1 and PD-L12▲ 33×1 topic
- Cancer Therapy2▲ 6.0×9 topics
- Metastatic Breast Cancer2▲ 58×2 topics
- Antigen Presentation1▲ 35×2 topics
- Cancer Genomics1▲ 43×1 topic
- Molecular Characterization1▲ 17×5 topics
- Molecular Subtypes1▲ 38×2 topics
- Mutational Signatures1▲ 43×1 topic
- Survival1▲ 23×3 topics
- Survival Analysis1▲ 11×5 topics
Which research topics does Tisch Cancer Institute publish most on?
By volume in 2022–2025: Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Lung Cancer Treatments and Mutations and Cancer Immunotherapy and Biomarkers.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Multiple Myeloma Research and Treatments Hematology 2 works
- 2 CAR-T cell therapy research Oncology 2 works
- 3 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 4 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 5 Cancer Genomics and Diagnostics Cancer Research 1 works
- 6 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 7 Breast Cancer Treatment Studies Cancer Research 1 works
- 8 Immunotherapy and Immune Responses Immunology 1 works
- 9 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 1 works
- 10 Bladder and Urothelial Cancer Treatments Surgery 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Tisch Cancer Institute's research output changed?
Output in 2018–2022 was 91% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in New York
- Flatiron Institute
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center
- Herbert Irving Comprehensive Cancer Center
- Microsoft Research New York City (United States)
- ICAP Global Health
- Fox Corporation (United States)
- Jane Street (United States)
- The Human Diagnosis Project
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.